Temodar Side Effects

Generic Name: temozolomide

Note: This page contains side effects data for the generic drug temozolomide. It is possible that some of the dosage forms included below may not apply to the brand name Temodar.

It is possible that some side effects of Temodar may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to temozolomide: oral capsule

As well as its needed effects, temozolomide (the active ingredient contained in Temodar) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking temozolomide, check with your doctor immediately:

Less common or rare
  • Amnesia
  • black, tarry stools
  • blood in the urine or stools
  • convulsions
  • cough or hoarseness
  • fever or chills
  • lower back or side pain
  • muscle weakness or paralysis on one or both sides of the body
  • painful or difficult urination
  • pinpoint red spots on the skin
  • swelling of the feet or lower legs
  • unusual bleeding or bruising
Incidence not known
  • Abdominal or stomach pain or tenderness
  • blistering, peeling, or loosening of the skin
  • chest pain
  • clay colored stools
  • cough
  • decreased appetite
  • diarrhea
  • difficulty swallowing
  • dizziness
  • fast heartbeat
  • headache
  • hives, itching, or skin rash
  • joint or muscle pain
  • nausea or vomiting
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • sneezing
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • tightness in the chest
  • troubled breathing
  • unusual tiredness or weakness
  • yellow skin or eyes

Some temozolomide side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common
  • Constipation
Less common or rare
  • Anxiety
  • blurred or double vision
  • breast pain (in females)
  • burning or prickling feeling on the skin
  • confusion
  • diarrhea
  • difficulty with speaking
  • drowsiness
  • increased urge to urinate
  • loss of appetite
  • loss of muscle coordination
  • mental depression
  • runny or stuffy nose
  • trouble sleeping
  • unusual weight gain

For Healthcare Professionals

Applies to temozolomide: intravenous powder for injection, oral capsule

Gastrointestinal

Very common (10% or more): Constipation (Up to 33%), nausea (Up to 53%), vomiting (Up to 42%), diarrhea (16%)
Common (1% to 10%): Abdominal pain, diarrhea, stomatitis, taste perversion, dysphagia, dyspepsia
Uncommon (0.1% to 1%): Abdominal distension, fecal incontinence, gastrointestinal disorder, gastroenteritis, hemorrhoids

General

The most common side effects were alopecia, nausea, vomiting, anorexia, headache, and constipation.

Nervous system

Very common (10% or more): Headache (Up to 41%), convulsions (Up to 23%), hemiparesis (18%), abnormal coordination (11%)
Common (1% to 10%): Dizziness, confusion, memory impairment, amnesia, paresthesia, somnolence, paresis, urinary incontinence, ataxia, abnormal gait, neuropathy, balance impairment, speech disorder, tremors, hemiparesis

Cardiovascular

Very common (10% or more): Peripheral edema (11%)
Uncommon (0.1% to 1%): Palpitation

Other

Very common (10% or more): Fatigue (Up to 61%), asthenia (13%), fever (13%)
Common (1% to 10%): Weakness, radiation injury, face edema, pain, hearing impairment
Uncommon (0.1% to 1%): Otitis media, tinnitus, hyperacusis, earache, deafness, vertigo, impotence, vaginal hemorrhage, menorrhagia, amenorrhea, vaginitis, breast pain

Endocrine

Common (1% to 10%): Adrenal hypercorticism

Respiratory

Common (1% to 10%): Cough, dyspnea, upper respiratory tract infection, pharyngitis, sinusitis
Post-marketing surveillance: Interstitial pneumonitis, pneumonitis, alveolitis, pulmonary fibrosis

Dermatologic

A case of diffuse erythematous skin rash that progressed to an extensive full body desquamative skin rash has been reported. Even though temozolomide (the active ingredient contained in Temodar) was permanently discontinued, the patient continued to experience the rash on a long-term basis with periodic exacerbations.

Very common (10% or more): Alopecia (55 to 69%), rash (13 to 19%)
Common (1% to 10%): Dry skin, erythema, pruritus, petechiae
Uncommon (0.1% to 1%): Photosensitivity reaction, abnormal pigmentation, sweating increased
Post-marketing surveillance: Toxic epidermal necrolysis, Stevens-Johnson syndrome

Psychiatric

Common (1% to 10%): Insomnia, anxiety, depression
Uncommon (0.1% to 1%): Agitation, apathy, behavior disorder, hallucination, amnesia

Metabolic

Very common (10% or more): Anorexia (19 to 27%)
Common (1% to 10%): Weight increase, weight decrease, hyperglycemia
Uncommon (0.1% to 1%): Hypokalemia

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain

Ocular

Common (1% to 10%): Vision blurred, diplopia
Uncommon (0.1% to 1%): Hemianopia, visual acuity reduced, vision disorder, visual field defect, eye pain, dry eyes

Immunologic

Common (1% to 10%): Infection, Herpes simplex, wound infection, candidiasis oral
Uncommon (0.1% to 1%): Herpes zoster, influenza-like symptoms
Post-marketing surveillance: Opportunistic infections including Pneumocystis pneumonia

Oncologic

Post-marketing surveillance: Secondary malignancies including myeloid leukemia

Hematologic

Common (1% to 10%): Thrombocytopenia, hemorrhage, leukopenia, neutropenia, lymphopenia, febrile neutropenia, anemia
Post-marketing surveillance: Prolonged pancytopenia, myelodysplastic syndrome

Hepatic

Common (1% to 10%): ALT increased
Uncommon (0.1% to 1%): Hepatic enzymes increased, Gamma GT increased, AST increased
Post-marketing surveillance: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, hepatitis

Hypersensitivity

Common (1% to 10%): Allergic reaction

Renal

Common (1% to 10%): Urinary tract infection, micturition increased frequency
Uncommon (0.1% to 1%): Dysuria

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)